ANI Pharmaceuticals vs Kiniksa Pharmaceuticals International
ANIP and KNSA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ANIP and KNSA compare
Kiniksa Pharmaceuticals International is the larger company, worth 9.3 times as much as ANI Pharmaceuticals ($14.9B against $1.6B).
On earnings, ANI Pharmaceuticals is cheaper: it trades at 14.9× trailing earnings, against 73.2× for Kiniksa Pharmaceuticals International.
Kiniksa Pharmaceuticals International grew revenue faster over the last twelve months (58.2% versus 30.9% for ANI Pharmaceuticals).
Kiniksa Pharmaceuticals International keeps more of each dollar of sales as profit, with a net margin of 11.6% compared with 11.1% at ANI Pharmaceuticals.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ANIP | KNSA |
|---|---|---|
| Size and price | ||
| Market cap | $1.6B | $14.9B |
| Share price | $69.99 | $95.11 |
| Change, 1 year | −16.7% | 136% |
| Change, 5 years | 71.7% | 716% |
| Beta (5Y) | 0.65 | 0.15 |
| Employees | 970 | 366 |
| StockData Score | ||
| Total score | 14 | 14 |
| Valuation score | 5 (better) | 0 |
| Growth score | 2 | 4 (better) |
| Performance score | 4 | 4 |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 14.9× (better) | 73.2× |
| P/S | 1.6× (better) | 15.8× |
| P/B | 2.7× (better) | 21.0× |
| EV/EBITDA | 6.6× (better) | 109× |
| P/FCF | 9.3× (better) | 75.8× |
| FCF yield | 10.8% (better) | 1.3% |
| Fair value | $133.72 | $16.72 |
| Margin of safety | 47.7% (better) | −469% |
| Growth | ||
| Revenue growth (TTM) | 30.9% | 58.2% (better) |
| Revenue growth, 5Y average | 33.5% | – |
| Net income growth (TTM) | – | 205% |
| EPS growth (TTM) | – | 189% |
| Profitability | ||
| Gross margin | 60.4% | 90.2% (better) |
| Operating margin | 15.4% (better) | 13.8% |
| Net margin | 11.1% | 11.6% (better) |
| FCF margin | 17.7% | 20.8% (better) |
| Return on equity | 21.0% (better) | 17.6% |
| Return on invested capital | 21.3% | 60.2% (better) |
| Financial health | ||
| Debt / equity | 0.50 (better) | 0.00 |
| Net debt / EBITDA | −0.25 | – |
| Interest coverage | 4.8× | – |
| Current ratio | 2.91 | 3.91 (better) |
| Altman Z-score | 2.53 | 34.40 (better) |
| Piotroski F-score | 7 | 8 (better) |
| Dividends and buybacks | ||
| Payout ratio | 0.32% | – |
| Buyback yield | 1.4% | – |
| Shareholder yield | 1.4% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 100% | 29.9% |
| Held by insiders | 12.3% | 5.1% |
| Insider net buying, 12 months | −$13.6M (better) | −$122M |
| Short interest, % of float | 17.8% | 2.9% |
Go deeper
- ANIP stock overview
- ANIP income statement
- ANIP valuation and score
- KNSA stock overview
- KNSA income statement
- KNSA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.